Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin for Pyloric Drainage in Esophagectomy
NCT02965976Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2016
- Primary completion
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of botulinum toxin type A in gastroparesis (2 arms), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Delayed Gastric Emptying Assessed Radiographically by Nuclear Medicine Emptying Study. Started Dec 2016; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
gastroparesis
Beyond the preview
Go deeper on NCT02965976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02965976.